Akèy › Rabdomiyosakòm
Etid klinik pou Rabdomiyosakòm ap rekrite nan Etazini
26 etid pou Rabdomiyosakòm ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX6 etid
- Memphis, TN6 etid
- Washington, DC5 etid
- Boston, MA4 etid
- Salt Lake City, UT4 etid
- Philadelphia, PA4 etid
- Seattle, WA3 etid
- Aurora, CO3 etid
- Birmingham, AL3 etid
- The Bronx, NY3 etid
- Dallas, TX3 etid
- Baltimore, MD3 etid
Pa eta
- Alabama3 etid
- Colorado3 etid
- Distrik Columbia4 etid
- Florid3 etid
- Kalifòni7 etid
- Maryland4 etid
- Massachusetts4 etid
- New York4 etid
- Ohio5 etid
- Pennsylvania5 etid
- Tennessee8 etid
- Texas9 etid
- Utah4 etid
- Washington3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Ap rekriteFaz 1
Laj 3 a 39 · Tout sèks · Mizajou Sep 29, 2026 · NCT06865664Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Ap rekriteFaz 1
24 Months – 18 Years · Tout sèks · Mizajou Sep 25, 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Sep 3, 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Ap rekriteFaz 3
Jiska laj 50 · Tout sèks · Mizajou Aug 25, 2026 · NCT07466316Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Ap rekrite
Tout laj · Tout sèks · Mizajou Aug 21, 2026 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Ap rekriteFaz 1
Laj 1 a 23 · Tout sèks · Mizajou Aug 13, 2026 · NCT07172958Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Aug 6, 2026 · NCT04715191Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT05210374Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Ap rekriteFaz 1/2
Laj 1 a 30 · Tout sèks · Mizajou Jul 22, 2026 · NCT06721689Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Ap rekrite
Jiska laj 39 · Tout sèks · Mizajou Jul 13, 2026 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Jun 30, 2026 · NCT06625190Familial Investigations of Childhood Cancer Predisposition
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jun 17, 2026 · NCT03050268Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Ap rekriteFaz 2
Jiska laj 22 · Tout sèks · Mizajou Jun 15, 2026 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Ap rekriteFaz 1/2
6 Months – 30 Years · Tout sèks · Mizajou Jun 2, 2026 · NCT04796012B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou May 19, 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou May 19, 2026 · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Apr 15, 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Ap rekriteFaz 2
Laj 1 a 50 · Tout sèks · Mizajou Mar 13, 2026 · NCT01804634Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Ap rekriteFaz 1/2
Laj 12 a 49 · Tout sèks · Mizajou Feb 19, 2026 · NCT06709495Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Ap rekriteFaz 1
Laj 1 a 26 · Tout sèks · Mizajou Feb 17, 2026 · NCT07148050HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Ap rekriteFaz 1
Laj 1 a 25 · Tout sèks · Mizajou Jan 22, 2026 · NCT04995003Molecular Analysis Of Solid Tumors
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Nov 12, 2025 · NCT01050296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Nov 3, 2025 · NCT06198296Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Ap rekriteFaz 1
7 Months – 21 Years · Tout sèks · Mizajou Oct 16, 2025 · NCT02508038Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.